Saturday 14 November 2026
  • About
  • Contact
  • Login
  • VC & Investment
  • M&A
  • AI
  • Podcasts
  • News
    • Pharmaceutical News
    • Biotechnology News
    • Generics News
    • Biosimilars news
    • In Brief
    • Legal
    • Company Pages
    • In The Boardroom
  • Insights
    • Analysis
    • Special Report
    • Interviews
    • Expert View
    • From Our Correspondent
    • One To Watch Companies
    • Digital Pharma
    • Pharma Leaders
  • Regulatory
    • FDA
    • EMA
    • Pricing, Reimbursement and Access
    • Regulation
    • Government Affairs
    • Trump Administration
  • Therapy Areas
    • Dermatologicals
    • Oncology
    • Neurological
    • Rare Diseases
    • Hematology
    • Cardio Vascular
    • Diabetes
    • Cell And Gene Therapy
  • Conferences
    • JPM Healthcare Conference
    • ESMO
    • ASCO
    • ASH
    • EULAR
    • AAIC
    • EASD
    • Conference News
  • Ones to Watch
  • About
  • Contact
  • Newsletter
  • Sign inSubscribe
Subscribe
  • Home
  • Europeans more interested in medical/ health research than economic/social news

Europeans more interested in medical/ health research than economic/social news

30 September 2007

People in the European Union are more interested in the results of medical and health research than in international, economic and social news, according to a new Eurobarometer report.

A survey conducted for the European Commission by Eurobarometer confirms that there is a strong interest in most European countries, particularly in the old European Union member states, in health research as well as in science and technology. The interest is even higher than in international news and economic and social affairs, it notes.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Try before you buy

 

Free

7 day trial access

Take a Free Trial
  • All the news that moves the needle in pharma and biotech
  • Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
  • Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





More ones to watch >


Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news






Today's issue

Regeneron touts positive POTS Phase II results for baloncibart
Biotechnology
Regeneron touts positive POTS Phase II results for baloncibart
14 November 2026
Biotechnology
Surrozen announces pricing of $60 million public offering
14 November 2026
Pharmaceutical
Russia may seize IP rights of foreign drugmakers leaving the country
13 November 2026
Biotechnology
CGT Catapult chief Matthew Durdy to retire in 2027 after 15 years
13 November 2026
Pharmaceutical
EMA-CHMP November meeting backs 3 novel medicines
13 November 2026
Biotechnology
Kamau’s gene-corrected sickle cell therapy nula-cel gets FDA RMAT designation on three-patient data
13 November 2026
Pharmaceutical
Novo files for etavopivat approval with FDA and EMA for sickle cell disease
13 November 2026


Company Spotlight

Altimmune
A late clinical-stage biopharmaceutical company developing pemvidutide, a balanced glucagon/GLP-1 dual receptor agonist, across three serious liver disease indications: MASH, alcohol use disorder, and alcohol-associated liver disease.




The Pharma Letter

39-43 Putney High Street, Putney
London, SW15 1SP
United Kingdom


  • About us
  • Contact
  • Subscribe
  • Sponsorship/advertising
  • Company News Directory


  • Terms and Conditions
  • Privacy Policy
  • Twitter
  • Linkedin
Copyright © The Pharma Letter 2026

 |  Headless Content Management with Blaze